Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes

References

• Horie Y Kanada S Watada H Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients Clin Ther 2011 33 973 989 21723606
   PubMed Web of Science ®Google Scholar
• Deacon CF Holst JJ Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes Expert Opin Investig Drugs 2010 19 133 140
   PubMed Web of Science ®Google Scholar
• Forst T Uhlig-Laske B Ring A Ritzhaupt A Graefe-Mody U Dugi KA The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus Diabetes Obes Metab 2011 13 542 550 21352464
   PubMed Web of Science ®Google Scholar
• Del PS Barnett AH Huisman H Neubacher D Woerle HJ Dugi KA Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Diabetes Obes Metab 2011 13 258 267 21205122
   PubMed Web of Science ®Google Scholar
• Forst T Pfutzner A Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes Expert Opin Pharmacother 2012 13 101 110 22149370
   PubMed Web of Science ®Google Scholar
• Del Prato S Linagliptin for the treatment of type 2 diabetes Expert Opin Pharmacother 2011 12 2759 2762 21883034
   PubMed Web of Science ®Google Scholar
• Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 1441 1467 21812507
   PubMed Web of Science ®Google Scholar
• Scheen AJ A review of gliptins in 2011 Expert Opin Pharmacother 2012 13 81 99 22149369
   PubMed Web of Science ®Google Scholar
• Retlich S Duval V Ring A Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg–10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects Clin Pharmacokinet 2010 49 829 840 21053992
   PubMed Web of Science ®Google Scholar
• Huttner S Graefe-Mody EU Withopf B Ring A Dugi KA Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers J Clin Pharmacol 2008 48 1171 1178 18812608
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Giessmann T Ring A Iovino M Woerle HJ A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects Clin Ther 2011 33 1096 1103 21803422
   PubMed Web of Science ®Google Scholar
• Heise T Graefe-Mody EU Huttner S Ring A Trommeshauser D Dugi KA Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients Diabetes Obes Metab 2009 11 786 794 19476474
   PubMed Web of Science ®Google Scholar
• Blech S Ludwig-Schwellinger E Grafe-Mody EU Withopf B Wagner K The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans Drug Metab Dispos 2010 38 667 678 20086031
   PubMed Web of Science ®Google Scholar
• [Trajenta product information]. Ingelheim am Rhein: Boehringer Ingelheim GmbH. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Accessed March 13, 2012.
   Google Scholar
• Eckhardt M Langkopf E Mark M 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes J Med Chem 2007 50 6450 6453 18052023
   PubMed Web of Science ®Google Scholar
• Barnett AH Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy Adv Ther 2011 28 447 459 21603986
   PubMed Web of Science ®Google Scholar
• Schernthaner G Barnett AH Emser A Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus Diabetes Obes Metab 2012 14 470 478 22268497
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Rose P Ring A Zander K Iovino M Woerle HJ Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects Drug Metab Pharmacokinet 2011 26 123 129 21084763
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU Jungnik A Ring A Woerle HJ Dugi KA Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers Int J Clin Pharmacol Ther 2010 48 652 661 20875371
   PubMed Web of Science ®Google Scholar
• Graefe-Mody EU Padula S Ring A Withopf B Dugi KA Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects Curr Med Res Opin 2009 25 1963 1972 19552619
   PubMed Web of Science ®Google Scholar
• Monami M Dicembrini I Martelli D Mannucci E Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials Curr Med Res Opin 2011 27 Suppl 3 57 64 22106978
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Rose P Retlich S Pharmacokinetics of linagliptin in subjects with hepatic impairment Br J Clin Pharmacol 2012 74 75 85 22242621
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U Friedrich C Port A Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*) Diabetes Obes Metab 2011 13 939 946 21672124
   PubMed Web of Science ®Google Scholar
• Johansen OE Neubacher D vonEynatten M Patel S Woerle HJ Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 2012 11 3 22234149
   PubMed Web of Science ®Google Scholar
• Ta NN Schuyler CA Li Y Lopes-Virella MF Huang Y DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice J Cardiovasc Pharmacol 2011 58 157 166 21558879
   PubMed Web of Science ®Google Scholar
• Davidson EP Coppey LJ Dake B Yorek MA Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications Exp Diabetes Res 2011 2011 Article ID 810469
   Google Scholar
• Monami M Lamanna C Desideri CM Mannucci E DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis Adv Ther 2012 29 14 25 22215383
   PubMed Web of Science ®Google Scholar
• Taskinen MR Rosenstock J Tamminen I Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2011 13 65 74 21114605
   PubMed Web of Science ®Google Scholar
• Gomis R Espadero RM Jones R Woerle HJ Dugi KA Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes Obes Metab 2011 13 653 661 21410628
   PubMed Web of Science ®Google Scholar
• Owens DR Swallow R Dugi KA Woerle HJ Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study Diabet Med 2011 28 1352 1361 21781152
   PubMed Web of Science ®Google Scholar